TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-03-06
徐志宏Hsu, Chih-Hung
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
33筆
31
Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer. 2019 Mar;8(2):110-120. doi: 10.1159/000489021. Epub 2018 Jun 15. PMID: 31019901; PMCID: PMC6465685.
32
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613. PMID: 31582355.
33
Liu TH, Shao YY, Lu LC, Shen YC, Hsu C, Lin ZZ, Hsu CH, Cheng AL. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):615-621. doi: 10.1080/17474124.2019.1621165. Epub 2019 May 27. PMID: 31132887.
